Search research articles
Contact Us
Filters
Showing results (111-120 of 129) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Blood
|
April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy
Prokop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.
Blood Advances
|
December 14, 2022
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 19, 2015
Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Veronika Bachanova, Linda J Burns, Kwang Woo Ahn, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Blood Advances
|
March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Blood
|
August 28, 2014
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, et al.
Journal of Hematology & Oncology
|
July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Cancer
|
October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure
Emily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 129) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Blood
|
April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy
Prokop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.
Blood Advances
|
December 14, 2022
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 19, 2015
Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Veronika Bachanova, Linda J Burns, Kwang Woo Ahn, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Blood Advances
|
March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Blood
|
August 28, 2014
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, et al.
Journal of Hematology & Oncology
|
July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Cancer
|
October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure
Emily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Page
of 13